Depression and Pharmacogenetics.

Autor: Ampong DN; Assistant Professor of Nursing, University of Alaska, Anchorage, College of Health, School of Nursing, 3321 Providence DR, Anchorage, AK 99508, United States.. Electronic address: dnampong@alaska.edu.
Jazyk: angličtina
Zdroj: Archives of psychiatric nursing [Arch Psychiatr Nurs] 2018 Feb; Vol. 32 (1), pp. 71-74. Date of Electronic Publication: 2017 Oct 16.
DOI: 10.1016/j.apnu.2017.10.011
Abstrakt: Depression is the most common and leading devastating psychiatric illness that affects a majority of the world population. The treatment of depression has been a challenge for a majority of patients and healthcare practitioners. The advent of pharmacogenomics (PGx) empowered the Food and Drug Administration to approve some antidepressant biomarkers for PGx model of treatment. The PGx testing identifies whether an individual is a poor metabolizer, ultra/rapid metabolizer, intermediate metabolizer, or essential metabolizer of an antidepressants before prescription. This is a cutting edge treatment that eliminates trial and error. PGx testing has shown to precisely identify the effective medication and dose for a patient.
(Copyright © 2017 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: